Confronta i metodi
Esamina i metodi selezionati fianco a fianco; le righe che differiscono sono evidenziate.
| UCLA Prostate Cancer Index× | EORTC QLQ-LC13: Qualità della Vita nel Cancro del Polmone× | |
|---|---|---|
| Campo | Oncologia | Oncologia |
| Famiglia | Process / pipeline | Process / pipeline |
| Anno di origine≠ | 1998 | 1994 |
| Ideatore≠ | Litwin, M. S., et al. | Bergman, B., et al. (EORTC Quality of Life Group) |
| Tipo | Self-report questionnaire | Self-report questionnaire |
| Fonte seminale≠ | Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., & Brook, R. H. (1998). The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care, 36(7), 1002–1012. DOI ↗ | Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994). The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer, 30A(5), 635–642. DOI ↗ |
| Alias≠ | UCLA PCI, PCI | QLQ-LC13 |
| Correlati | 5 | 5 |
| Sintesi≠ | The UCLA Prostate Cancer Index (UCLA PCI) is a 20-item, prostate-cancer-specific quality-of-life instrument focused on functional outcomes (urinary, sexual, bowel) rather than general cancer QoL. Developed by Litwin et al. in 1998, it has become the standard functional assessment tool in prostate cancer outcomes research, particularly for treatment comparison studies evaluating surgical vs. radiation outcomes. | The EORTC QLQ-LC13 is a 13-item lung-cancer-specific module designed to complement the 30-item EORTC QLQ-C30 core questionnaire. Developed and validated by Bergman et al. in 1994, it measures lung-specific symptoms (dyspnea, cough, hemoptysis, chest pain) and treatment toxicities (sore mouth, dysphagia). It is the standard lung cancer-specific QoL instrument in European and international trials. |
| ScholarGateInsieme di dati ↗ |
|
|